Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 22; no. 10; pp. 3355 - 3363
• Main Authors: Hasan, Diya, Ismail, Yazan, Al Tibi, Ahmad, Al-Zeidaneen, Safaa A, Odeh, Mohanad, Burghel, George J, Natsheh, Iyad, Abdelnour, Amid
• Format: Journal Article
• Language: English
• Published: Thailand West Asia Organization for Cancer Prevention 01-10-2021
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apolipoproteins B - blood; Biomarkers - blood; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Bridged-Ring Compounds - administration & dosage; Bridged-Ring Compounds - adverse effects; C-Reactive Protein - metabolism; Cardiotoxicity - diagnosis; Cardiotoxicity - etiology; Chemotherapy, Adjuvant - adverse effects; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Female; Humans; Middle Aged; Risk Assessment; Taxoids - administration & dosage; Taxoids - adverse effects; Hs-CRP; breast cancer; Chemotherapy; cardiotoxicity; Apo-B
• ISSN: 1513-7368; 2476-762X
• DOI: 10.31557/APJCP.2021.22.10.3355

This study aimed to investigate level fluctuations of serum biomarkers that are associated with cardiotoxicity risk, such as high-sensitivity C-reactive protein (hs-CRP) and apolipoprotein-B (Apo-B) in response to chemotherapy treatment for breast cancer.
The serum levels of hs-CRP and Apo-B were evaluated in 56 breast cancer patients with main inclusion criteria: HER2 negative and who received adjuvant chemotherapy AC [A: Adriamycin, C: Cyclophosphamide] or AC→T [A: Adriamycin, C: Cyclophosphamide, T: Taxane] regimes at early II (n = 26) and late IV (n = 30) clinical stages by using particle enhanced turbidimetric assay.
The results of this study suggest that a high level of pre-treatment hs-CRP is a good prognostic marker in comparison to Apo-B. Moreover, the AC-T chemotherapy regime treatment in both early and late stages exhibited a significantly higher level of hs-CRP compared to that in the AC regime. Hs-CRP was significantly elevated in the early stage in comparison to the late stage among cancer patients, meanwhile Apo-B behaved inversely. Furthermore, the results showed that hs-CRP levels were significantly higher in late-stage cancer patients compared with those in early-stage in both chemotherapy regimens groups. On the other hand, Apo-B showed no significant differences.
Monitoring hs-CRP level changes in comparison to Apo-B can be used to assist the side effect risk difference among different chemotherapy regimens, and staging reflecting a positive correlation between them more notable in the late stage.